Suwon, South Korea

Ji Soo Ahn

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2012.


% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:

goldMedal1 out of 834,350 
Other
 patents

Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Ji Soo Ahn

Introduction

Ji Soo Ahn is a notable inventor based in Suwon, South Korea. She has made significant contributions to the field of biotechnology, particularly in the development of human interferon-beta muteins. Her work has implications for therapeutic applications, showcasing her innovative spirit and dedication to advancing medical science.

Latest Patents

Ji Soo Ahn holds a patent for a human interferon-beta mutein. This invention relates specifically to a human interferon-beta mutein that possesses one or two additional sugar chains compared to natural human interferon-beta. This advancement could enhance the efficacy of treatments involving interferon-beta, which is crucial in managing various diseases.

Career Highlights

Throughout her career, Ji Soo Ahn has demonstrated a commitment to research and innovation. Her work has not only contributed to her field but has also paved the way for future advancements in biotechnology. With a patent portfolio that includes 1 patent, she continues to be a driving force in her area of expertise.

Collaborations

Ji Soo Ahn has collaborated with notable colleagues, including Kyung Jun Song and Tae Ho Byun. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and innovation.

Conclusion

Ji Soo Ahn's contributions to biotechnology, particularly through her patent on human interferon-beta muteins, highlight her role as an influential inventor. Her work exemplifies the impact of innovation in the medical field, and she continues to inspire future generations of scientists and inventors.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…